These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8071039)

  • 21. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).
    Döhr O; Hofmeister R; Treher M; Schweinfurth H
    Invest Radiol; 2007 Dec; 42(12):830-41. PubMed ID: 18007155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Toxicity of aequous iodated contrast substances after TavegylR (Sandoz) (author's transl)].
    Svoboda M; Puchta V
    Cesk Radiol; 1975 Jul; 29(4):273-4. PubMed ID: 1149167
    [No Abstract]   [Full Text] [Related]  

  • 23. Preclinical characterization of iopromide-carrying liposomes.
    Krause W; Sachse A; Wagner S; Kollenkirchen U; Rössling G
    Invest Radiol; 1991 Nov; 26 Suppl 1():S172-4; discussion S175-6. PubMed ID: 1808120
    [No Abstract]   [Full Text] [Related]  

  • 24. Cystographic contrast media: clinical and experimental studies.
    McAlister WH; Griffith RC
    AJR Am J Roentgenol; 1983 Nov; 141(5):997-1001. PubMed ID: 6605077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
    Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
    Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Contrast tolerance during angiography, with special reference to blood electrolyte changes].
    Löhr E; Makoski HB; Fiebach O
    Fortschr Geb Rontgenstr Nuklearmed; 1972 Mar; 116(3):367-73. PubMed ID: 4338839
    [No Abstract]   [Full Text] [Related]  

  • 27. Preclinical testing of iopromide. 2nd communication: toxicological evaluation.
    Krause W; Schöbel C; Press WR
    Arzneimittelforschung; 1994 Nov; 44(11):1275-9. PubMed ID: 7848345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Experimental studies on altering the properties of the prosthetic plastic, Kallocryl B, by adding an x-ray contrast medium].
    Deutschmann R; Gehre G
    Stomatol DDR; 1980 Jul; 30(7):475-81. PubMed ID: 7008273
    [No Abstract]   [Full Text] [Related]  

  • 29. Selection of intravascular contrast media in clinical radiology.
    Boijsen E
    Acta Radiol Suppl; 1983; 366():180-4. PubMed ID: 6433654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles.
    Na HB; Lee JH; An K; Park YI; Park M; Lee IS; Nam DH; Kim ST; Kim SH; Kim SW; Lim KH; Kim KS; Kim SO; Hyeon T
    Angew Chem Int Ed Engl; 2007; 46(28):5397-401. PubMed ID: 17357103
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug evaluation: Lymphoseek - Neoprobe's sentinel lymph node imaging agent for use in cancer patients.
    de Paulis T
    Curr Opin Investig Drugs; 2006 Dec; 7(12):1100-7. PubMed ID: 17209528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography.
    Steger-Hartmann T; Graham PB; Müller S; Schweinfurth H
    Invest Radiol; 2006 May; 41(5):449-59. PubMed ID: 16625108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contrast media and enzyme inhibition. I. Cholinesterase.
    Dawson P; Edgerton D
    Br J Radiol; 1983 Sep; 56(669):653-6. PubMed ID: 6883032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted dendrimer-based contrast agents for articular cartilage assessment by MR imaging.
    Winalski CS; Shortkroff S; Schneider E; Yoshioka H; Mulkern RV; Rosen GM
    Osteoarthritis Cartilage; 2008 Jul; 16(7):815-22. PubMed ID: 18226558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contrast media in angiography. State of the art and future prospects.
    Amiel MJ
    Radiol Med; 1986 Jun; 72(6 Suppl 1):2-8. PubMed ID: 3523638
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical experience with isopaque-300 in excretory urography and evaluation of cerebral electrical activity.
    Seabury JC; Erwin CU; Boyarsky S
    J Urol; 1968 Nov; 100(5):701-3. PubMed ID: 5682552
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of intravascular injections of contrast media on the cerebral circulation.
    Taylor AR
    Br J Radiol; 1973 May; 46(545):402. PubMed ID: 4715168
    [No Abstract]   [Full Text] [Related]  

  • 38. Blood-pool magnetic resonance imaging contrast agents. New developments.
    Doucet D; Urvoas E; Kravtzoff R; Chambon C; Schoumann-Claeys E; Frija G; Ropars C
    Invest Radiol; 1991 Nov; 26 Suppl 1():S46-7; discussion S60-4. PubMed ID: 1808148
    [No Abstract]   [Full Text] [Related]  

  • 39. [Contrast media in use in myelography and ventriculography: current status and future prospects].
    Gonsette RE
    Radiol Med; 1980 Apr; 66(4):195-202. PubMed ID: 6256823
    [No Abstract]   [Full Text] [Related]  

  • 40. Renal tolerance of nonionic dimers.
    Deray G; Jacobs C
    Invest Radiol; 1996 Jun; 31(6):372-7. PubMed ID: 8761871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.